SBRT plus abiraterone acetate and ADT versus abiraterone acetate and ADT in oligometastatic castrate-resistant prostate cancer (ARTO): long-term, unplanned overall survival analysis of an open-label, randomised, phase 2 trial

The Lancet Oncology 2026 Open access

Read full text
Authors: Giulio Francolini, Vanessa Di Cataldo, Saverio Caini, Pietro Garlatti, Michele Aquilano, Niccolò Bertini, Alessio Bruni, Gianluca Ingrosso, Rolando Maria D’Angelillo, Luca Tagliaferri, Barbara A Jereczek-Fossa, Matteo Augugliaro
+26 more Luca Triggiani, Silvana Parisi, Lorenzo Masieri, Riccardo Campi, Richard Kenneth Valicenti, Gabriele Simontacchi, Daniela Greto, Pierluigi Bonomo, Mauro Loi, Chad Tang, Lorenzo Livi, Giulia Marvaso, Filippo Alongi, Andrea Gaetano Allegra, Andrea Lancia, Fabio Arcidiacono, Annamaria Vinciguerra, Ciro Franzese, Giorgia Timon, Cinzia Iotti, Monica Mangoni, Isacco Desideri, Icro Meattini, Carlotta Becherini, Raffaela Doro, Laura Masi
DOI: 10.1016/s1470-2045(26)00178-6
Cited by: 1
References: 17

Fields of Study & Subjects

Prostate Cancer Treatment and Research Prostate Cancer Diagnosis and Treatment Radiopharmaceutical Chemistry and Applications

Publication details

Journal / source
The Lancet Oncology
Publisher
Elsevier BV
Volume
27
Issue
7
Pages
830–838
Publication date
29 June 2026
Language
EN